Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing trial studying the impact of the drug datopotamab deruxtecan on breast cancer patients.
The pharmaceutical behemoth reported that the drug illustrated a “statistically significant and clinically meaningful improvement” in progression-free survival in comparison to chemotherapy. The Phase III trial, TROPION-Breast01, focused on patients suffering from inoperable or metastatic hormone receptor (HR)-positive, HER2-low, or negative breast cancer who had undergone prior endocrine and systemic therapy. The drug is particularly aimed at those who have developed resistance to other treatments.
Susan Galbraith, AstraZeneca’s oncology vice president, remarked, “The news from today’s TROPION-Breast01 is a momentous advancement for such patients,” adding that they are buoyed by the favourable outcomes.
The ongoing trial’s results, conducted in partnership with Japanese company Daiichi Sankyo, are slated for presentation at a forthcoming meeting. Ken Takeshita, the head of oncology at Daiichi Sankyo, commented on the positive topline results, emphasizing their demonstration of the potential of datopotamab deruxtecan to evolve into a significant treatment alternative.
He expressed anticipation towards uncovering the full potential of this antibody-drug conjugate across various breast cancer subtypes through their continuing Phase III program.
